Biotech entity
Of the tracked stories, 1 of 2 also mention ANKTIVA, the most common co-covered peer. That works out to roughly 0.9 stories per week across a 16-day span. Their average consequence score of 7 runs above the beat's 6 for that window.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention ANKTIVA, the most common co-covered peer. That works out to roughly 0.9 stories per week across a 16-day span. Their average consequence score of 7 runs above the beat's 6 for that window. Each story carries 2.5 original sources on average, compared with 3.5 for the broader beat in this window. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. European Medicines Agency appears in 2 tracked Biotech stories published from February 18, 2026 through March 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 172 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering European Medicines Agency. Shared-story counts are live from our verified record — not editorial picks.
Target Commercialization
Anticipated EU launch for iopofosine I 131 treatment of WM.
EMA Submission
Target window for filing the CMA for iopofosine I 131 in the European Union.
CLR 125 Data Readout
Expected early data from the Phase 1b study in Triple Negative Breast Cancer.
Annual Results Announcement
CEO James Caruso provides corporate updates and confirms regulatory timelines.
Fiscal Year End
Cellectar concludes a year focused on pipeline execution and supply chain strengthening.
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Source: The Motley Fool · AOL.com
European Medicines Agency is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
